Evidence map›Paper›PMID 32360882›Full record

ArticleThe Journal of infection2020

Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort.

Tongai G Maponga, Anna L McNaughton, Marije van Schalkwyk, Susan Hugo, Chikezie Nwankwo, Jantjie Taljaard, Jolynne Mokaya, David A Smith, Cloete van Vuuren, Dominique Goedhals and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Observational
  11. Article
  12. Review
  13. Article
  14. HBV-Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Tongai G MapongaDivision of Medical Virology, Stellenbosch University / National Health Laboratory Service Tygerberg, Cape Town, South Africa.
Anna L McNaughtonNuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, Oxford, UK.
Marije van SchalkwykDivision of Infectious Diseases, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa.
Susan HugoDivision of Infectious Diseases, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa.
Chikezie NwankwoDivision of Gastroenterology, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa.
Jantjie TaljaardDivision of Infectious Diseases, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa.
Jolynne MokayaNuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, Oxford, UK.
David A SmithNuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, Oxford, UK.
Cloete van VuurenDivision of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Dominique GoedhalsDivision of Virology, Universitas Academic Laboratories, National Health Laboratory Service/University of the Free State, Bloemfontein, South Africa.
Shiraaz GabrielDivision of Gastroenterology, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa.
Monique I AnderssonDivision of Medical Virology, Stellenbosch University / National Health Laboratory Service Tygerberg, Cape Town, South Africa; Department of Microbiology and Infectious Diseases, Oxford University Hospitals, John Radcliffe Hospital, Headington, Oxford, UK.
Wolfgang PreiserDivision of Medical Virology, Stellenbosch University / National Health Laboratory Service Tygerberg, Cape Town, South Africa.
Christo van RensburgDivision of Gastroenterology, Department of Medicine, Stellenbosch University / Tygerberg Academic Hospital, Cape Town, South Africa.
Philippa C MatthewsNuffield Department of Medicine, University of Oxford, Medawar Building, South Parks Road, Oxford, UK; Department of Microbiology and Infectious Diseases, Oxford University Hospitals, John Radcliffe Hospital, Headington, Oxford, UK; NIHR British Research Council, John Radcliffe Hospital, Headington, Oxford, UK. Electronic address: philippa.matthews@ndm.ox.ac.uk.
Stellenbosch University · ZAUniversity of Oxford · GBNational Health Laboratory Service · ZAUniversity of the Free State · ZA

Funding

Wellcome TrustWellcome Trust 110110/Z/15/Z
6 · The paper itself

Abstract

objectivesPrompted by international targets for elimination of hepatitis B virus (HBV), we set out to characterise individuals with HBV monoinfection vs. those coinfected with HBV/HIV, to evaluate the impact of therapy and to guide improvements in clinical care.

methodsWe report observational data from a real world cross-sectional cohort of 115 adults with chronic hepatitis B infection (CHB), at a university hospital in Cape Town, South Africa. HIV coinfection was present in 39 (34%) subjects. We recorded cross-sectional demographic, clinical and laboratory data.

resultsCompared to those with HIV coinfection, HBV monoinfected adults were less likely to be HBeAg-positive (p=0.01), less likely to have had assessment with elastography (p<0.0001), and less likely to be on antiviral treatment (p<0.0001); they were more likely to have detectable HBV viraemia (p=0.04), and more likely to have features of liver disease including moderate/severe thrombocytopaenia (p=0.007), elevated bilirubin (p=0.004), and elevated APRI score (p=0.02). Three cases of hepatocellular carcinoma all arose in HBV monoinfection.

conclusionsOur data demonstrate that individuals with HBV monoinfection may be disadvantaged compared to those with HIV coinfection, highlighting potential systematic inequities in referral, monitoring and treatment.

Indexed as

CoinfectionHepatitis BHIV InfectionsAdultCross-Sectional StudiesHepatitis B virusHumansSouth AfricaCoinfectionDolutegravirEliminationHBVHepatitis B virusHepatocellular carcinomaHIVSouth AfricaSustainable development goalsTenofovirTreatmentViral load

Identifiers

PMID32360882
PMCPMC7308798
OpenAlexW3020957886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.